282 related articles for article (PubMed ID: 11522229)
1. The biology of natural killer cells and implications for therapy of human disease.
Chiorean EG; Miller JS
J Hematother Stem Cell Res; 2001 Aug; 10(4):451-63. PubMed ID: 11522229
[TBL] [Abstract][Full Text] [Related]
2. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
Guo H; Qian X
Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
[TBL] [Abstract][Full Text] [Related]
3. Targeted cellular therapy with natural killer cells.
Klingemann H; Boissel L
Horm Metab Res; 2008 Feb; 40(2):122-5. PubMed ID: 18283630
[TBL] [Abstract][Full Text] [Related]
4. Challenges of cancer therapy with natural killer cells.
Klingemann H
Cytotherapy; 2015 Mar; 17(3):245-9. PubMed ID: 25533934
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor.
Mingari MC; Vitale C; Cantoni C; Bellomo R; Ponte M; Schiavetti F; Bertone S; Moretta A; Moretta L
Eur J Immunol; 1997 Jun; 27(6):1374-80. PubMed ID: 9209487
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
[TBL] [Abstract][Full Text] [Related]
7. NK cell-based cancer immunotherapy: from basic biology to clinical application.
Li Y; Yin J; Li T; Huang S; Yan H; Leavenworth J; Wang X
Sci China Life Sci; 2015 Dec; 58(12):1233-45. PubMed ID: 26588912
[TBL] [Abstract][Full Text] [Related]
8. Lysis of pig endothelium by IL-2 activated human natural killer cells is inhibited by swine and human major histocompatibility complex (MHC) class I gene products.
Itescu S; Artrip JH; Kwiatkowski PA; Wang SF; Minanov OP; Morgenthau AS; Michler RE
Ann Transplant; 1997; 2(1):14-20. PubMed ID: 9869836
[TBL] [Abstract][Full Text] [Related]
9. Infusions of allogeneic natural killer cells as cancer therapy.
Leung W
Clin Cancer Res; 2014 Jul; 20(13):3390-400. PubMed ID: 24987108
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cells: the journey from puzzles in biology to treatment of cancer.
Bodduluru LN; Kasala ER; Madhana RM; Sriram CS
Cancer Lett; 2015 Feb; 357(2):454-67. PubMed ID: 25511743
[TBL] [Abstract][Full Text] [Related]
11. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules.
Tallerico R; Todaro M; Di Franco S; Maccalli C; Garofalo C; Sottile R; Palmieri C; Tirinato L; Pangigadde PN; La Rocca R; Mandelboim O; Stassi G; Di Fabrizio E; Parmiani G; Moretta A; Dieli F; Kärre K; Carbone E
J Immunol; 2013 Mar; 190(5):2381-90. PubMed ID: 23345327
[TBL] [Abstract][Full Text] [Related]
12. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
13. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer.
Ruggeri L; Mancusi A; Capanni M; Martelli MF; Velardi A
Curr Opin Immunol; 2005 Apr; 17(2):211-7. PubMed ID: 15766683
[TBL] [Abstract][Full Text] [Related]
14. NK cell-based immunotherapy for cancer.
Fang F; Xiao W; Tian Z
Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
[TBL] [Abstract][Full Text] [Related]
15. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.
Tonn T; Becker S; Esser R; Schwabe D; Seifried E
J Hematother Stem Cell Res; 2001 Aug; 10(4):535-44. PubMed ID: 11522236
[TBL] [Abstract][Full Text] [Related]
16. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells.
Karlhofer FM; Ribaudo RK; Yokoyama WM
Nature; 1992 Jul; 358(6381):66-70. PubMed ID: 1614533
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cells for osteosarcoma.
Tarek N; Lee DA
Adv Exp Med Biol; 2014; 804():341-53. PubMed ID: 24924184
[TBL] [Abstract][Full Text] [Related]
19. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of human and mouse natural killer tumor recognition using retroviral antisense in primary natural killer cells: involvement with MHC class I killer cell inhibitory receptors.
Ortaldo JR; Mason AT; Mason LH; Winkler-Pickett RT; Gosselin P; Anderson SK
J Immunol; 1997 Feb; 158(3):1262-7. PubMed ID: 9013968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
